期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Changing paradigm of cancer therapy:precision medicine by next-generation sequencing 被引量:3
1
作者 Yuan Xue william r.wilcox 《Cancer Biology & Medicine》 SCIE CAS CSCD 2016年第1期12-18,共7页
Precision medicine aims to identify the right drug, for the right patient, at the right dose, at the right time, which is particularly important in cancer therapy. Problems such as the variability of treatment respons... Precision medicine aims to identify the right drug, for the right patient, at the right dose, at the right time, which is particularly important in cancer therapy. Problems such as the variability of treatment response and resistance to medication have been longstanding challenges in oncology, especially for development of new medications. Solid tumors, unlike hematologic malignancies or brain tumors, are remarkably diverse in their cellular origins and developmental timing. The ability of next-generation sequencing(NGS) to analyze the comprehensive landscape of genetic alterations brings promises to diseases that have a highly complex and heterogeneous genetic composition such as cancer. Here we provide an overview of how NGS is able to facilitate precision medicine and change the paradigm of cancer therapy, especially for solid tumors, through technical advancements, molecular diagnosis, response monitoring and clinical trials. 展开更多
关键词 癌症治疗 医学 测序 药物治疗 发育时间 脑肿瘤 恶性肿瘤 血液系统
下载PDF
Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing 被引量:1
2
作者 Christine Stanislaw Yuan Xue william r.wilcox 《Cancer Biology & Medicine》 SCIE CAS CSCD 2016年第1期55-67,共13页
The introduction of next-generation sequencing(NGS) technology in testing for hereditary cancer susceptibility allows testing of multiple cancer susceptibility genes simultaneously. While there are many potential bene... The introduction of next-generation sequencing(NGS) technology in testing for hereditary cancer susceptibility allows testing of multiple cancer susceptibility genes simultaneously. While there are many potential benefits to utilizing this technology in the hereditary cancer clinic, including efficiency of time and cost, there are also important limitations that must be considered. The best panel for the given clinical situation should be selected to minimize the number of variants of unknown significance. The inclusion in panels of low penetrance or newly identified genes without specific actionability can be problematic for interpretation.Genetic counselors are an essential part of the hereditary cancer risk assessment team, helping the medical team select the most appropriate test and interpret the often complex results. Genetic counselors obtain an extended family history, counsel patients on the available tests and the potential implications of results for themselves and their family members(pre-test counseling), explain to patients the implications of the test results(post-test counseling), and assist in testing family members at risk. 展开更多
关键词 遗传性 癌症 遗传评价 检测 测序 基因测试 遗传咨询 测试技术
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部